Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases
Open Access
- 13 November 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 148 (9) , 2203-2211
Abstract
Observational studies in prostate cancer (PCa) have shown an increased risk of cardiovascular disease (CVD) following gonadotropin‐releasing hormone (GnRH) agonists, whereas randomised‐controlled trials have shown no associations. Compared to GnRH agonists, GnRH antagonists have shown less atherosclerotic effects in preclinical models. We used real‐world data from five countries to investigate CVD risk following GnRH agonists and antagonists in PCa men. Data sources included cancer registries, primary and secondary healthcare databases. CVD event was defined as an incident or fatal CVD. Multivariable Cox proportional hazard models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), which were pooled using random‐effects meta‐analysis. Stratified analyses were conducted by history of CVD and age (75 years). A total of 48 757 men were on GnRH agonists and 2144 on GnRH antagonists. There was no difference in risk of any CVD for men on GnRH antagonists and agonists (HR: 1.25; 95% CI: 0.96‐1.61; I2: 64%). Men on GnRH antagonists showed increased risk of acute myocardial infarction (HR: 1.62; 95% CI: 1.11‐2.35; I2: 0%) and arrhythmia (HR: 1.55; 95% CI: 1.11‐2.15, I2: 17%) compared to GnRH agonists. Having a history of CVD was found to be an effect modifier for the associations with some CVD subtypes. Overall, we did not observe a difference in risk of overall CVD when comparing GnRH antagonists with agonists—though for some subtypes of CVD we noted an increased risk with antagonists. Further studies are required to address potential confounding caused by unadjusted variables such as severity of CVD history and PCa stage.Keywords
Funding Information
- Ferring
This publication has 32 references indexed in Scilit:
- GnRH blockers: a changing paradigm in the management of prostate cancerInternational Journal of Urological Nursing, 2009
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular MortalityJNCI: Journal of the National Cancer Institute, 2007
- Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer, 2007
- Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial InfarctionsJournal of Clinical Oncology, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPDPharmacoepidemiology and Drug Safety, 2005
- Testosterone and Atherosclerosis in Aging MenAmerican Journal of Cardiovascular Drugs, 2005
- What are the Read Codes?Health Libraries Review, 1994
- The need for randomization in the study of intended effectsStatistics in Medicine, 1983